STAT3信号通路作为头颈癌的治疗靶点：障碍与创新
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
作者信息
Geiger Jessica L, Grandis Jennifer R, Bauman Julie E
机构信息
Department of Internal Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.
Department of Otolaryngology, University of California San Francisco, San Francisco, CA, United States.
出版信息
Oral Oncol. 2016 May;56:84-92. doi: 10.1016/j.oraloncology.2015.11.022. Epub 2015 Dec 28.
Abstract
Proteins of the signal transducer and activator of transcription (STAT) family mediate cellular responses to cytokines and growth factors. Aberrant regulation of the STAT3 oncogene contributes to tumor formation and progression in many cancers, including head and neck squamous cell carcinoma (HNSCC), where hyperactivation of STAT3 is implicated in both treatment resistance and immune escape. There are no oncogenic gain-of-function mutations in HNSCC. Rather, aberrant STAT3 signaling is primarily driven by upstream growth factor receptors, such as Janus kinase (JAK) and epidermal growth factor receptor (EGFR). Moreover, genomic silencing of select protein tyrosine phosphatase receptors (PTPRs), tumor suppressors that dephosphorylate STAT3, may lead to prolonged phosphorylation and activation of STAT3. This review will summarize current knowledge of the STAT3 pathway and its contribution to HNSCC growth, survival, and resistance to standard therapies, and discuss STAT3-targeting agents in various phases of clinical development.
摘要
信号转导与转录激活因子（STAT）家族的蛋白质介导细胞对细胞因子和生长因子的反应。STAT3癌基因的异常调控在包括头颈部鳞状细胞癌（HNSCC）在内的许多癌症中促进肿瘤形成和进展，其中STAT3的过度激活与治疗耐药性和免疫逃逸均有关联。HNSCC中不存在致癌性功能获得性突变。相反，异常的STAT3信号传导主要由上游生长因子受体驱动，如Janus激酶（JAK）和表皮生长因子受体（EGFR）。此外，选择性蛋白酪氨酸磷酸酶受体（PTPR）的基因组沉默，即使STAT3去磷酸化的肿瘤抑制因子，可能导致STAT3的磷酸化和激活延长。本综述将总结目前关于STAT3通路的知识及其对HNSCC生长、存活和对标准疗法耐药性的影响，并讨论处于临床开发不同阶段的STAT3靶向药物。
相似文献
1
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.STAT3信号通路作为头颈癌的治疗靶点：障碍与创新
Oral Oncol. 2016 May;56:84-92. doi: 10.1016/j.oraloncology.2015.11.022. Epub 2015 Dec 28.
2
Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.在头颈部鳞状细胞癌中，SOCS-1的表观遗传修饰通过JAK和/或MEK对白细胞介素-6受体和表皮生长因子受体信号作出反应，差异性地调节STAT3激活。
Mol Cancer Ther. 2006 Jan;5(1):8-19. doi: 10.1158/1535-7163.MCT-05-0069.
3
Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.联合靶向表皮生长因子受体、信号转导和转录激活因子-3以及Bcl-X(L)可增强头颈部鳞状细胞癌的抗肿瘤作用。
Mol Pharmacol. 2008 Jun;73(6):1632-42. doi: 10.1124/mol.107.044636. Epub 2008 Mar 6.
4
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.JAK激酶抑制可消除STAT3激活以及头颈部鳞状细胞癌肿瘤生长。
Neoplasia. 2015 Mar;17(3):256-64. doi: 10.1016/j.neo.2015.01.003.
5
Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).姜黄素（二阿魏酰甲烷）对头颈部鳞状细胞癌细胞中组成型和白细胞介素-6诱导型信号转导子及转录激活子3通路的靶向作用
Int J Cancer. 2006 Sep 15;119(6):1268-75. doi: 10.1002/ijc.21967.
6
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.定义 JAK-STAT 通路在头颈部和胸部恶性肿瘤中的作用：对未来治疗方法的影响。
Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14.
7
Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中NFκB和STAT3信号通路之间的分子串扰
Neoplasia. 2006 Sep;8(9):733-46. doi: 10.1593/neo.06274.
8
Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer.头颈部癌症中信号转导与转录激活因子3（STAT3）的综述
Oral Oncol. 2015 Jun;51(6):565-9. doi: 10.1016/j.oraloncology.2015.03.004. Epub 2015 Mar 25.
9
(-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.(-)-表没食子儿茶素没食子酸酯通过抑制头颈部鳞状细胞癌细胞中组成性和 IL-6 诱导的 JAK/STAT3 信号传导诱导 Fas/CD95 介导的细胞凋亡。
J Agric Food Chem. 2012 Mar 14;60(10):2480-9. doi: 10.1021/jf204362n. Epub 2012 Mar 5.
10
Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.古柯脂醇（GS）可抑制无烟烟草和尼古丁诱导的头颈癌细胞中的 NF-κB 和 STAT3 通路。
Carcinogenesis. 2011 Mar;32(3):368-80. doi: 10.1093/carcin/bgq278. Epub 2010 Dec 22.
引用本文的文献
1
Comparative Transcriptomic Analysis of the Liver and Spleen in Ussuri Catfish () Challenged with Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)).用聚肌苷酸-聚胞苷酸（Poly(I:C)）刺激的乌苏里鲶肝脏和脾脏的比较转录组分析
Animals (Basel). 2025 Aug 21;15(16):2454. doi: 10.3390/ani15162454.
2
Applications of nanomaterials in head and neck squamous cell carcinoma: current progress and perspectives.纳米材料在头颈部鳞状细胞癌中的应用：当前进展与展望
Discov Nano. 2025 Aug 18;20(1):141. doi: 10.1186/s11671-025-04328-1.
3
Head and neck tumor organoid grown under simplified media conditions model tumor biology and chemoradiation responses.在简化培养基条件下培养的头颈部肿瘤类器官可模拟肿瘤生物学特性及放化疗反应。
Sci Rep. 2025 Jul 7;15(1):24221. doi: 10.1038/s41598-025-88082-5.
4
assessment of BBI608 in 2D and 3D culture models for drug repositioning in oral squamous cell carcinoma.在二维和三维培养模型中评估BBI608用于口腔鳞状细胞癌的药物重新定位
Oncol Rep. 2025 Aug;54(2). doi: 10.3892/or.2025.8930. Epub 2025 Jun 20.
5
Discovery of benzethonium chloride as a potent STAT3 inhibitor for the treatment of HNSCC.发现苄索氯铵作为一种有效的信号转导和转录激活因子3（STAT3）抑制剂用于治疗头颈部鳞状细胞癌（HNSCC）。
Front Pharmacol. 2025 Apr 2;16:1569570. doi: 10.3389/fphar.2025.1569570. eCollection 2025.
6
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?靶向 STAT3 用于癌症治疗：聚焦于 Y705、S727 或双重抑制？
Cancers (Basel). 2025 Feb 23;17(5):755. doi: 10.3390/cancers17050755.
7
Phytochemicals and their Nanoformulations for Overcoming Drug Resistance in Head and Neck Squamous Cell Carcinoma.用于克服头颈部鳞状细胞癌耐药性的植物化学物质及其纳米制剂
Pharm Res. 2025 Mar;42(3):429-449. doi: 10.1007/s11095-025-03836-0. Epub 2025 Mar 3.
8
Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors.对舌鳞状细胞癌免疫类型进行分层以改善预后及对免疫检查点抑制剂的反应。
Cancer Immunol Immunother. 2025 Mar 1;74(4):130. doi: 10.1007/s00262-025-03982-9.
9
Understanding the role of nerves in head and neck cancers - a review.了解神经在头颈癌中的作用——综述
Oncol Rev. 2025 Jan 20;18:1514004. doi: 10.3389/or.2024.1514004. eCollection 2024.
10
Insights into expression and localization of HPV16 LCR-associated transcription factors and association with LCR activity in HNSCC.头颈部鳞状细胞癌中HPV16长控制区相关转录因子的表达、定位及其与长控制区活性的关系
Mol Ther Oncol. 2024 Dec 21;33(1):200926. doi: 10.1016/j.omton.2024.200926. eCollection 2025 Mar 20.
本文引用的文献
1
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.功能缺失性PTPRD突变导致头颈部癌中STAT3激活增加及对STAT3抑制的敏感性增强。
PLoS One. 2015 Aug 12;10(8):e0135750. doi: 10.1371/journal.pone.0135750. eCollection 2015.
2
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.Fedratinib 治疗原发性或继发性骨髓纤维化患者的安全性和疗效：一项随机临床试验。
JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590.
3
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.托法替尼，一种口服 Janus 激酶抑制剂，用于治疗慢性斑块状银屑病：两项随机、安慰剂对照、III 期临床试验的结果。
Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018.
4
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.蛋白酪氨酸磷酸酶受体 T（PTPRT）启动子频繁的高甲基化增加头颈部癌中信号转导与转录激活因子 3（STAT3）的激活及对 STAT3 抑制的敏感性。
Oncogene. 2016 Mar 3;35(9):1163-9. doi: 10.1038/onc.2015.171. Epub 2015 May 18.
5
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.OPB-51602（一种信号转导和转录激活因子3口服抑制剂）用于复发/难治性血液系统恶性肿瘤患者的I期研究。
Cancer Sci. 2015 Jul;106(7):896-901. doi: 10.1111/cas.12683. Epub 2015 May 25.
6
NF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma.核因子-κB和信号转导与转录激活因子3转录因子特征可区分人乳头瘤病毒阳性和阴性的头颈部鳞状细胞癌。
Int J Cancer. 2015 Oct 15;137(8):1879-89. doi: 10.1002/ijc.29558. Epub 2015 Jun 23.
7
Quercetin Down-regulates IL-6/STAT-3 Signals to Induce Mitochondrial-mediated Apoptosis in a Nonsmall- cell Lung-cancer Cell Line, A549.槲皮素下调IL-6/STAT-3信号通路以诱导非小细胞肺癌细胞系A549发生线粒体介导的凋亡。
J Pharmacopuncture. 2015 Mar;18(1):19-26. doi: 10.3831/KPI.2015.18.002.
8
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.JAK激酶抑制可消除STAT3激活以及头颈部鳞状细胞癌肿瘤生长。
Neoplasia. 2015 Mar;17(3):256-64. doi: 10.1016/j.neo.2015.01.003.
9
Dose selection of siltuximab for multicentric Castleman's disease.用于多中心Castleman病的西妥昔单抗的剂量选择。
Cancer Chemother Pharmacol. 2015 May;75(5):1037-45. doi: 10.1007/s00280-015-2720-0. Epub 2015 Mar 18.
10
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3).找准靶点：新型强效信号转导与转录激活因子3（STAT3）抑制剂OPB-31121的作用机制
Mol Oncol. 2015 Jun;9(6):1194-206. doi: 10.1016/j.molonc.2015.02.012. Epub 2015 Mar 5.
Zotero 插件